Compare MAX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAX | MLYS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 2.4B |
| IPO Year | 2020 | 2023 |
| Metric | MAX | MLYS |
|---|---|---|
| Price | $9.53 | $23.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $14.58 | ★ $48.67 |
| AVG Volume (30 Days) | 966.3K | ★ 1.1M |
| Earning Date | 04-29-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.81 | ★ 37.43 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $1,113,600,000.00 | N/A |
| Revenue This Year | $12.70 | N/A |
| Revenue Next Year | $9.32 | N/A |
| P/E Ratio | $24.95 | ★ N/A |
| Revenue Growth | ★ 28.78 | N/A |
| 52 Week Low | $7.09 | $10.44 |
| 52 Week High | $13.92 | $47.65 |
| Indicator | MAX | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 30.24 |
| Support Level | $9.45 | $13.42 |
| Resistance Level | $10.93 | $31.09 |
| Average True Range (ATR) | 0.41 | 1.76 |
| MACD | 0.01 | -0.30 |
| Stochastic Oscillator | 16.17 | 11.34 |
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.